Haplotype diversity of 17 Y-STR in the Iranian population.

The current study aimed to evaluate Y chromosome haplotypes obtained from 1353 unrelated Iranian males using the AmpFlSTRTM YfilerTM kit; 1353 out of the 1353 identified haplotypes were unique. The haplotype diversity (HD) and discriminating capacity (DC) values were 1.00000 and 0.997, respectively. Analysis of genetic distance was performed using molecular variance (AMOVA) and multidimensional scaling plots (MDS), revealing a statistically significant difference between the study population and previous data reported for other Iranian populations and other neighboring countries. The present findings are likely to be useful for forensic casework analyses and kinship investigations.

Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model.

Background: Overexpression of programmed cell death ligand 1 (PD-L1) in tumor cells and subsequent interaction with the programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells cause an immune evasion of the tumor from cytotoxic T-cells. Therefore, inhibiting such interaction by a recombinant PD-1 can hinder tumor growth and extend the survival rate. Methods: The mouse extracellular domain of PD-1 (mPD-1) was expressed in E. coli BL21 (DE3) strain and purified using nickel affinity chromatography. The binding ability of the purified protein to human PD-L1 was studied using ELISA. Finally, the tumor-bearing mice were used to evaluate the potential antitumor effect. Results: The recombinant mPD-1 showed a significant binding capacity to human PD-L1 at the molecular level. The tumor size significantly decreased in the tumor-bearing mice after the intra-tumoral injections of mPD-1. Moreover, the survival rate increased significantly after eight weeks of monitoring. The histopathology revealed the necrosis in the tumor tissue of the control group compared to the mPD-1 received mice. Conclusions: Our outcomes propose that interaction blockade between PD-1 and PD-L1 is a promising approach for targeted tumor therapy.

In Vivo Tumor Therapy with Novel Immunotoxin Containing Programmed Cell Death Protein-1 and Diphtheria Toxin.

Immunotoxins, as a class of antitumor agents, consist of tumor-selective ligands linked to highly toxic protein molecules. This type of modified antibody has been designed for the therapy of cancers and a few viral infections. In this study, we designed immunotoxin consisting of mouse programmed cell death protein-1 (PD1), which genetically fused to diphtheria toxin (DT) subunit A (DT386). DNA construct was cloned, expressed in a bacterial system, purified, and confirmed by western blotting. The immunotoxin potency in the treatment of tumorous C57BL/6 mice was evaluated. Immunotoxin was injected intratumoral to mice, and through eight injections, 67% of the tumor volume of the test group started shrinking dramatically. On the contrary, the tumor size of the control group, treated with phosphate-buffered saline, continued its growth. The successful targeting of solid tumor cells by PD1-DT immunotoxin demonstrates the potential therapeutic utility of these conjugates.

Solid phase extraction of ultra traces mercury (II) using octadecyl silica membrane disks modified by 1,3-bis(2-ethoxyphenyl)triazene (EPT) ligand and determination by cold vapor atomic absorption spectrometry.

A facile and highly efficient method was developed for the preconcentration of the ultra trace amounts of mercury (II) ions. Octadecyl silica membrane disk was modified by the recently synthesized triazene ligand, 1,3-bis(2-ethoxyphenyl)triazene (EPT), and cold vapor atomic absorption spectrometry was used to determine the resultant preconcentrated Hg(II) ions. Solution studies with EPT and a series of metal ions were done in advance, and the results showed a strong affinity of EPT to the mercury ions. To perform solid phase extraction, various parameters such as pH of the sample, flow rates and the amount of the ligand were optimized. A linear calibration curve was obtained in the range of 0.02-1.90 µg L(-1) with r(2) = 0.9990 (n = 8), and the limit of detection (LOD) based on three times the standard deviation of the blank was 10.6 ng L(-1). The relative standard deviation (RSD) for the determination of 0.1 µg L(-1) Hg(II) found to be 2.9% while a RSD value of 1.1% was obtained for the determination of 1.0 µg L(-1) Hg(II) (n = 8). The preconcentration and improvement factors were 380 and 74, respectively. The newly developed method was successfully applied to the determination of mercury ions in real water samples.